438 related articles for article (PubMed ID: 17136399)
1. Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings.
Sinha R; Kimmerling A; Doebrick C; Kosten TR
Psychopharmacology (Berl); 2007 Mar; 190(4):569-74. PubMed ID: 17136399
[TBL] [Abstract][Full Text] [Related]
2. Lofexidine in Combination With Oral Naltrexone for Opioid Use Disorder Relapse Prevention: A Pilot Randomized, Double-Blind, Placebo-Controlled Study.
Hermes G; Hyman SM; Fogelman N; Kosten TR; Sinha R
Am J Addict; 2019 Nov; 28(6):480-488. PubMed ID: 31448846
[TBL] [Abstract][Full Text] [Related]
3. Stress and drug-cue-induced craving in opioid-dependent individuals in naltrexone treatment.
Hyman SM; Fox H; Hong KI; Doebrick C; Sinha R
Exp Clin Psychopharmacol; 2007 Apr; 15(2):134-43. PubMed ID: 17469937
[TBL] [Abstract][Full Text] [Related]
4. A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal.
Gorodetzky CW; Walsh SL; Martin PR; Saxon AJ; Gullo KL; Biswas K
Drug Alcohol Depend; 2017 Jul; 176():79-88. PubMed ID: 28527421
[TBL] [Abstract][Full Text] [Related]
5. Buprenorphine for managing opioid withdrawal.
Gowing L; Ali R; White JM; Mbewe D
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD002025. PubMed ID: 28220474
[TBL] [Abstract][Full Text] [Related]
6. Opioid antagonists with minimal sedation for opioid withdrawal.
Gowing L; Ali R; White JM
Cochrane Database Syst Rev; 2017 May; 5(5):CD002021. PubMed ID: 28553701
[TBL] [Abstract][Full Text] [Related]
7. Lofexidine: A Newly FDA-Approved, Nonopioid Treatment for Opioid Withdrawal.
Doughty B; Morgenson D; Brooks T
Ann Pharmacother; 2019 Jul; 53(7):746-753. PubMed ID: 30724094
[TBL] [Abstract][Full Text] [Related]
8. Clonidine Maintenance Prolongs Opioid Abstinence and Decouples Stress From Craving in Daily Life: A Randomized Controlled Trial With Ecological Momentary Assessment.
Kowalczyk WJ; Phillips KA; Jobes ML; Kennedy AP; Ghitza UE; Agage DA; Schmittner JP; Epstein DH; Preston KL
Am J Psychiatry; 2015 Aug; 172(8):760-7. PubMed ID: 25783757
[TBL] [Abstract][Full Text] [Related]
9. Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.
Law FD; Diaper AM; Melichar JK; Coulton S; Nutt DJ; Myles JS
J Psychopharmacol; 2017 Aug; 31(8):1046-1055. PubMed ID: 28631527
[TBL] [Abstract][Full Text] [Related]
10. Lofexidine versus diazepam for the treatment of opioid withdrawal syndrome: A double-blind randomized clinical trial in Singapore.
Guo S; Manning V; Yang Y; Koh PK; Chan E; de Souza NN; Assam PN; Sultana R; Wijesinghe R; Pangjaya J; Kandasami G; Cheok C; Lee KM; Wong KE
J Subst Abuse Treat; 2018 Aug; 91():1-11. PubMed ID: 29910009
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans.
Walsh SL; Strain EC; Bigelow GE
Addiction; 2003 Apr; 98(4):427-39. PubMed ID: 12653813
[TBL] [Abstract][Full Text] [Related]
12. In-patient detoxification procedures, treatment retention, and post-treatment opiate use: comparison of lofexidine + naloxone, lofexidine + placebo, and methadone.
McCambridge J; Gossop M; Beswick T; Best D; Bearn J; Rees S; Strang J
Drug Alcohol Depend; 2007 Apr; 88(1):91-5. PubMed ID: 17064857
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Lofexidine for Medically Managed Opioid Withdrawal: A Randomized Controlled Clinical Trial.
Fishman M; Tirado C; Alam D; Gullo K; Clinch T; Gorodetzky CW;
J Addict Med; 2019; 13(3):169-176. PubMed ID: 30531234
[TBL] [Abstract][Full Text] [Related]
14. Lofexidine versus clonidine in rapid opiate detoxification.
Gerra G; Zaimovic A; Giusti F; Di Gennaro C; Zambelli U; Gardini S; Delsignore R
J Subst Abuse Treat; 2001 Jul; 21(1):11-7. PubMed ID: 11516922
[TBL] [Abstract][Full Text] [Related]
15. [A double-blind randomized placebo-controlled study of the efficacy of the combined treatment with naltrexone and guanfacine for relapse prevention in opiate dependence].
Krupitsky EM; Blokhina EA; Zvartau EE; Verbitskaya VE; Bushara EM; Tiurina AA; Palatkin VY; Yaroslavtseva TS; Burakov AM; Masalov DV; Romanova TN; Grininko AY; Sinha R; Kosten T
Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(10):39-46. PubMed ID: 26525620
[TBL] [Abstract][Full Text] [Related]
16. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse.
Haney M; Hart CL; Vosburg SK; Comer SD; Reed SC; Foltin RW
Psychopharmacology (Berl); 2008 Mar; 197(1):157-68. PubMed ID: 18161012
[TBL] [Abstract][Full Text] [Related]
17. Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial.
Levin FR; Mariani JJ; Pavlicova M; Brooks D; Glass A; Mahony A; Nunes EV; Bisaga A; Dakwar E; Carpenter KM; Sullivan MA; Choi JC
Drug Alcohol Depend; 2016 Feb; 159():53-60. PubMed ID: 26711160
[TBL] [Abstract][Full Text] [Related]
18. Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder.
Shi Z; Wang AL; Jagannathan K; Fairchild VP; O'Brien CP; Childress AR; Langleben DD
J Psychiatry Neurosci; 2018 Jul; 43(4):254-261. PubMed ID: 29947607
[TBL] [Abstract][Full Text] [Related]
19. Effect of lofexidine on cardiac repolarization during treatment of opioid withdrawal.
Darpö B; Pirner M; Longstreth J; Ferber G
Drug Alcohol Depend; 2019 Dec; 205():107596. PubMed ID: 31606589
[TBL] [Abstract][Full Text] [Related]
20. Randomised double-blind comparison of lofexidine and clonidine in the out-patient treatment of opiate withdrawal.
Carnwath T; Hardman J
Drug Alcohol Depend; 1998 May; 50(3):251-4. PubMed ID: 9649979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]